

## Overview of CML related sessions at EHA2024 Hybrid Congress

June 13-16, 2024 in Madrid (In-Person and live streamed program)

Time slots	Sessions
<b>CML sessions</b>	
<p>June 13 (Thursday)</p> <p>8.00 – 9.30 CEST</p> <p>Room: N103</p>	<p><b>Hybrid Satellite Symposium:</b> (Supported by Novartis)</p> <p>Beyond responses: Optimizing outcomes from the start of the chronic myeloid leukemia treatment journey</p> <p>Chair: Timothy Hughes (Australia)</p> <p>Program:</p> <ul style="list-style-type: none"> <li>• Beyond overall survival and achieving responses: what challenges remain when treating CML? (D. Žáčková, Czech Republic)</li> <li>• Novel treatment approaches: elevating the need for tolerability in treatment innovations (S. Saussele, Germany)</li> <li>• Tolerability as the foundation: optimizing outcomes from the start of the treatment journey (T. Hughes, Australia)</li> <li>• Is it time for tolerability to play a greater role in treatment decisions? (All faculty)</li> </ul>
<p>June 14 (Friday)</p> <p>8.00 – 9.30 CEST</p> <p>Room: Hall Dali 2</p>	<p><b>Education Session:</b> Updates in chronic myeloid leukemia (CML) management</p> <p>Chair: Delphine Réa (France)</p> <p>Program:</p> <ul style="list-style-type: none"> <li>• Targeting pathways outside BCR::ABL (M. Copland, UK)</li> <li>• The new treatment paradigms: Improving quality of life in CML (F. Efficace, Italy)</li> <li>• ELN Recommendations 2024 (H. Hjorth-Hansen, Norway)</li> </ul>

Time slots	Sessions
<p>June 14 (Friday)</p> <p>9.45 – 10.45 CEST</p> <p>Room: Hall Blanchard</p>	<p><b>Hematology-in-Focus-Session:</b> Chronic myeloid leukemia (CML)</p> <p>Chair: JWM Janssen (The Netherlands)</p> <p>Program:</p> <ul style="list-style-type: none"> <li>• When are alternative therapeutics indicated? (A. Hochhaus, Germany)</li> <li>• Management of CML patients in countries with limited resources (H. Malhotra, India)</li> <li>• Monitoring of CML patients during and after therapy (N. Cross, UK)</li> </ul>
<p>June 15 (Saturday)</p> <p>8.00 – 8.45</p> <p>Room: N105</p>	<p><b>Thematic debate:</b> Treatment of resistant chronic myeloid leukemia (CML): Advanced line drug therapy vs. allogeneic stem cell transplantation (Allo-SCT)</p> <p>Chair: D. Wolf (Austria)</p> <p>Program:</p> <ul style="list-style-type: none"> <li>• Pro: Advanced line drug therapy (V. García-Gutierrez, Spain)</li> <li>• Pro: Allogeneic stem cell transplantation (Y. Chalandon, Switzerland)</li> <li>• Debate (All speakers)</li> </ul>
<p>June 15 (Saturday)</p> <p>9.45 – 10.45</p> <p>Room: Hall Malo</p>	<p><b>Specialized Working Group Session:</b> ELN-EHA SWG for CML</p> <p>Chair: J Apperley (UK)</p> <p>Program:</p> <ul style="list-style-type: none"> <li>• Protac inhibition of BCR-ABL1 (tbd)</li> <li>• BCL2 family in myeloid malignancies (C. Heckman, Finland)</li> <li>• Potential for stem cell inhibition (D. Vetrie, UK)</li> </ul>

Time slots	Sessions
<b>Oral Sessions</b>	
June 15 (Saturday) 16.30 – 17.45 CEST  Room: Hall Malo	<b>Oral Session:</b> New diagnostic and prognostic tools for CML  Program and speakers tbd
June 16 (Sunday) 11.30 – 12.45 CEST  Room: Hall N104	<b>Oral Session:</b> Optimization and innovation in CML treatment  Program and speakers tbd
<b>Advocacy &amp; Patient Sessions</b>	
June 14 (Friday) 13.30 – 14.30 CEST  Room: N105	<b>EHA Symposium on Patient Education</b>  Program and speakers tbd

Information on abstracts and poster presentations will be provided soon.